Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 3/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NMT1 | P30419 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | JAK1 | P23458 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31198846 | 0.96 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL3577152 | 0.85 | HRH1 (0.51) | SMN1; SMN2NPC1RAB9ACYP2C19HRH1 | |
| SCHEMBL4618960 | 0.85 | HRH3 (0.54) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL7503285 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL4035554 | 0.83 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL8316392 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL15747803 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL30963412 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL6749001 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL13198831 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1883636-A1 | SUBSTITUTED PIPERIDINE ANTAGONIST OF HI RECEPTOR TO BE USED FOR THE TREATMENT OF RHINITIS | GLAXO GROUP LIMITED (GB) | 2008-02-06 | — | — | EP | disclosed |
| US-20060293298-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
| WO-2006125665-A1 | SUBSTITUTED PIPERIDINE ANTAGONIST OF HI RECEPTOR TO BE USED FOR THE TREATMENT OF RHINITIS | GLAXO GROUP LIMITED (GB) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293298-A1 | Compounds | NQO1, OPRM1, CAT | SMN1; SMN2 470/4885NPC1 10/4885RAB9A 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.